TiumBio Co., Ltd. (KOSDAQ:321550)
South Korea · Delayed Price · Currency is KRW 4,060.00
+125.00 (3.18%)
At close: Oct 16, 2026
TiumBio Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 14,997 | 12,289 | 6,792 | 4,899 | 9,118 | 56.8 |
Revenue Growth | 104.49% | 80.92% | 38.65% | -46.27% | 15952.75% | -94.58% |
Gross Profit Gross Profit Growth | 5,923 | 5,044 | 1,948 | 4,899 | 9,118 | 56.8 |
Operating Income Operating Income Growth | -16,082 | -16,139 | -18,699 | -27,832 | -25,640 | -32,696 |
Net Income Net Income Growth | -17,110 | -17,360 | -20,644 | -17,911 | -29,853 | -31,637 |
Earnings Per Share EPS Growth | -600.48 | -640.37 | -799.09 | -734.27 | -1246.00 | -1329.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Natural Cosmetics Natural Cosmetics Growth | 4,917 | 4,909 | - |
Biopharmaceutical Development and Production Biopharmaceutical Development and Production Growth | 10,080 | 7,380 | 6,792 |
Total Total Growth | 14,997 | 12,289 | 6,792 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 32,800 | 42,391 | 50,624 | 40,457 | 35,100 | 40,635 |
Total Debt Total Debt Growth | 28,561 | 32,153 | 30,180 | 29,000 | 23,211 | 19,474 |
Net Cash (Debt) Net Cash Growth | 4,239 | 10,238 | 20,444 | 11,457 | 11,889 | 21,161 |
Net Cash Growth | -70.12% | -49.92% | 78.44% | -3.63% | -43.82% | -68.57% |
Net Cash Per Share Net Cash Per Share Growth | 148.74 | 377.64 | 791.37 | 469.70 | 496.13 | 888.58 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -14,814 | -15,303 | -15,628 | -20,616 | -16,013 | -24,802 |
Capital Expenditures CapEx Growth | -880.35 | -264.34 | -1,040 | -18,336 | -11,185 | -11,845 |
Free Cash Flow Free Cash Flow Growth | -15,695 | -15,567 | -16,668 | -38,952 | -27,198 | -36,647 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 39.49% | 41.05% | 28.68% | 100.00% | 100.00% | 100.00% |
Operating Margin | -107.23% | -131.33% | -275.30% | -568.14% | -281.22% | -57566.15% |
Pretax Margin | -122.72% | -152.88% | -346.67% | -388.62% | -344.42% | -56785.56% |
Profit Margin | -114.09% | -141.27% | -303.93% | -365.62% | -327.42% | -55701.69% |
FCF Margin | -104.65% | -126.68% | -245.40% | -795.14% | -298.31% | -64522.48% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 8.13 | 13.88 | 16.55 | 49.11 | 33.19 | 8127.16 |